Document:

allstarexh10_10.htm

Exhibit 10.10

 

CONSULTING SERVICES AGREEMENT

 

This Consulting Agreement (the "Agreement") is entered into this 5th day of January, 2010 by and between:

 

	 	
IFG Investments Services, Inc., a Nevis Corporation 

Ram's Business Complex

Stoney Grove, Box 822

Charlestown, Nevis   Federation of St Kitts & Nevis

 

and 
	(the “Consultant”)
	 	 	 
	 	
China Qinba Pharmaceuticals, Inc., a Delaware Corporation

24th Floor, Building A

Zhengxin Mansion, No. 5 of 1st Gaoxin Road

Hi-Tech Development Zone

Xi’an City, Shaanxi Province

People’s Republic of China 
	(the “Company”)

 

RECITALS

 

WHEREAS, the Company is in need of assistance in the public company sector including advising on a merger/acquisition transaction, NASDAQ and Hong Kong Stock Exchange listing applications, SEC filings including but not limited to, Form 8-K, Registration Statement support;

WHEREAS, the Consultant has agreed to perform consulting work for the Company in providing merger/acquisition transaction support, NASDAQ and Hong Kong Stock Exchange listing applications support, SEC filings, including but not limited to, Form 8K and Registration Statement support and other consulting services and other related activities
as directed by the Company;  and

NOW, THEREFORE, the parties hereby agree as follows:

1. Consultant's Services. Consultant shall be available and shall provide to the Company professional consulting services in the areas of merger/acquisition transaction support, NASDAQ and Hong Kong Stock Exchange listing applications support SEC filings, including but not limited to,
Form 8K and Registration Statement support and other consulting services support ("Consulting services") as requested.

2. Consideration.

A. RATE.  In consideration for the Consulting Services to be performed by Consultant under this Agreement, the Company will issue the Consultant warrants to acquire 1,800,000 common shares of the Company’s stock, adjusted for any forward or reverse splits, with registration rights, at a
$0.83 exercise price and expiration date of three years after the closing of the acquisition or merger for time spent on Consulting Services.  (collectively, the “Warrants”)

B.  EXPENSES. Additionally, the Company will pay Consultant for the following expenses incurred while the Agreement between Consultant and the Company exists:

	
  
	
●
	
All travel expenses to and from all work sites

	
  
	
●
	
Meal expenses;

	
  
	
●
	
Administrative expenses;

	
  
	
●
	
Lodging Expenses if work demands overnight stays; and

	
  
	
●
	
Miscellaneous travel-related expenses (parking and tolls).

  

Page 1

  

Consultant shall submit written documentation and receipts where available itemizing the dates on which expenses were incurred. The Company shall pay Consultant the amounts due pursuant to submitted reports within 14 days after a report is received by the Company.

C. REGISTRATION RIGHTS: The Company will cause a registration statement to be filed with the U.S. Securities and Exchange Commission, covering 100% of the common stock underlying the Warrants, on or before May 31, 2010 and use its commercially reasonable efforts to cause the registration
statement to become effective within one hundred eighty (180) days following the date of this Agreement.  The Company will also use commercially reasonable efforts to maintain the effectiveness of the registration statement for a period of 3 years from the date of this Agreement.

 

The Company will be deemed not to have used commercially reasonable efforts to cause the registration statement to become, or to remain effective during the requisite period if the Company voluntarily takes any action that would, or omits any action the omission of which would result in either: (i) such registration statement not being declared
effective; or (ii) the holders of securities covered by a previously effective registration statement being prohibited by applicable law from trading the securities covered thereby.

 

The aggregate amount of liquidated damages payable by the Company to the Consultants as a result of a failure to timely file, or cause the registration statement to become or maintain its effective status, shall be capped at ten percent (10%) of the market value of the common stock underlying the Warrants at the time of breach.  Moreover,
the Company shall not accrue liquidated damages with respect to more than one of any failure under this section at a time.

D. SENIOR EXCHANGE LISTING: The Company will cause a listing application to be filed with the NASDAQ Exchange for the Capital Markets board within 9 months following the closing of the acquisition or merger. The Company will
maintain or ensure by reverse split that the share BID will remain at $4.00 within 9 months following the date of the closing of the acquisition or merger.  The Company will use commercially reasonable efforts to maintain the company in good standing and in good structure to meet the listing requirements of NASDAQ’s Capital Market.

The aggregate amount of liquidated damages payable by the Company to the Consultants as a result of a failure to timely file, or cause the listing application to become or maintain its listing status, or to fail to maintain the share BID at $4.00, shall be capped at the issuance of warrants to acquire 100,000 common shares of the company’s
common stock at a $0.83 per share exercise price with an expiration date of three years after the issuance of said warrants, for each and every month, or portion of any month, at the time of the breach. Moreover, the Company shall not accrue liquidated damages with respect to more than one of any failure under this section at a time.

3. Independent Contractor.  Nothing herein shall be construed to create an employer-employee relationship between the Company and Consultant. Consultant is an independent contractor and not an employee of the Company or any of its subsidiaries or affiliates. The consideration set
forth in Section 2 shall be the sole consideration due Consultant for the services rendered hereunder. It is understood that the Company will not withhold any amounts for payment of taxes from the compensation of Consultant hereunder. Consultant will not represent to be or hold herself out as an employee of the Company.

4. Confidentiality.  In the course of performing Consulting Services, the parties recognize that Consultant may come in contact with or become familiar with information which the Company or its subsidiaries or affiliates may consider confidential. This information may include, but
is not limited to, information pertaining to the Company [specify] systems, which information may be of value to a competitor. Consultant agrees to keep all such information confidential and not to discuss or divulge it to anyone other than appropriate Company personnel or their designees.

  

Page 2

  

5. Term. This Agreement shall commence on January 5, 2010 and shall terminate on a January 4, 2012, unless earlier terminated by either party hereto. Either party may terminate this Agreement upon Thirty (30) days prior written notice. The Company may, at its option, renew this Agreement
for an additional One (1) year term on the same terms and conditions as set forth herein by giving notice to Consultant of such intent to renew on or before January 4, 2012.

6. Notice.  Any notice or communication permitted or required by this Agreement shall be deemed effective when personally delivered or deposited, postage prepaid, in the first class mail of the United States properly addressed to the appropriate party at the address set forth below:

Notices to Consultant:

 

IFG Investments Services, Inc., a Nevis Corporation

Attention: Daniel MacMullin

Ram's Business Complex

Stoney Grove,

Box 822

Charlestown, Nevis

Federation of St Kitts & Nevis

Notices to the Company:

 

China Qinba Pharmaceuticals, Inc.

24th Floor, Building A

Zhengxin Mansion, No. 5 of 1st Gaoxin Road

Hi-Tech Development Zone

Xi’an City, Shaanxi Province

People’s Republic of China

7. Miscellaneous.

7.1 Entire Agreement and Amendments.  This Agreement constitutes the entire agreement of the parties with regard to the subject matter hereof, and replaces and supersedes all other agreements or understandings, whether written
or oral. No amendment or extension of the Agreement shall be binding unless in writing and signed by both parties.

7.2 Binding Effect, Assignment.  This Agreement shall be binding upon and shall inure to the benefit of Consultant and the Company and to the Company's successors and assigns. Nothing in this Agreement shall be construed to permit the assignment by Consultant of any of its rights
or obligations hereunder, and such assignment is expressly prohibited without the prior written consent of the Company.

7.3 Governing Law, Severability.  This Agreement shall be governed by the laws of the Nevis. The invalidity or unenforceability of any provision of the Agreement shall not affect the validity or enforceability of any other provision.

  

Page 3

  

WHEREFORE, the parties have executed this Agreement as of the date first written above.

China Qinba Pharmaceuticals, Inc.:

By: _______________________________________

Wang Guozhu, Chairman and Chief Executive Officer

Date: January 5, 2010

 

 

 

 

IFG Investments Services, Inc.

By:_______________________________________

Daniel MacMullin, President

January 5, 2010

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

Page 4allstarexh10_11.htm

Exhibit 10.11

 

HACG Investor Relations Services, Inc.

 

INVESTOR RELATIONS SERVICES AGREEMENT

 

 

THIS AGREEMENT (“Agreement”) dated January 27, 2010, is by and between:

 

HACG Investor Relations Services, Inc.  (the “Agency”)

Craigmuir Chambers

PO Box 71, Road Town, Tortola

VG1110  British Virgin Islands

 

and

 

China Qinba Pharmaceuticals, Inc., a Delaware Corporation  (the “Company”)

24th Floor, Building A, Zhengxin Mansion, No. 5 of 1st Gaoxin Road

Hi-Tech Development Zone, Xi’an City, Shaanxi Province

People’s Republic of China

 

 

RECITALS

WHEREAS, the Company is in need of assistance in the public company sector including advising on and with respect to investor relations services to be provided by Agency to China Qinba Pharmaceuticals, Inc.

NOW, THEREFORE, the parties hereby agree as follows:

 

SERVICES.  The Company hereby engages Agency to provide investor relations services to China Qinba Pharmaceuticals, Inc. as of February 1, 2010 until January 31, 2011.  Unless written notification is received 30 days in advance, the Agreement is automatically
renewable for one year.

 

TERM.  February 1, 2010 through January 31, 2011.

 

COMPENSATION.  Agency will receive in consideration for the Investor Relations Services to be performed by Consultant under this Agreement, the
Company will issue the Consultant warrants to acquire 1,200,000 Warrants to purchase common shares of the Company’s stock, adjusted for any forward or reverse splits, with registration rights, at a $0.83 exercise price and expiration date of January 31, 2013, for time spent on Consulting Services.   (collectively,
the “Warrants”)

 

EXPENSES.   During the Term, China Qinba Pharmaceuticals, Inc. will reimburse Agency for Agency’s actual, direct, out-of-pocket costs, for properly documented, verifiable, non-personal, reasonable business expenses incurred by
Agency in connection with and directly relating to Agency’s performance of its services under this Agreement, such as long distance telephone charges, photocopies at a rate not to exceed $.10 per copy, newswire distribution, postage and miscellaneous expenses as necessary.  Expenses in excess of $500 shall be approved in writing by the Company in advance.

 

REPRESENTATIONS/WARRANTIES.  Agency represents and warrants the following:

  

1

  

 

All of Agency’s services shall be provided in a timely and competent manner in accordance with industry quality standards;

 

Any materials or documents submitted, developed or created by Agency for China Qinba Pharmaceuticals, Inc. shall not violate or infringe upon a trademark, trade name, copyright, patent, literary or any other property right of any person or entity or constitute defamation, libel, slander, trade disparagement, plagiarism or an invasion
of privacy.

 

Agency has the right to enter into this Agreement and is free to enter and fully perform the services hereunder.  Agency does not have any contract or other agreement with any other person or entity which might conflict or interfere or be inconsistent with any of the provisions of this Agreement or the enjoyment by the Company
of any rights granted hereunder.

 

INDEMNIFICATION.  Agency shall indemnify and hold the Company harmless from and against any and all losses, damages, liabilities, claims, demands, suits and expenses (including reasonable attorneys’ fees) that the Company may incur
or be liable for as a result of any claim, suit, or proceeding made or brought against China Qinba Pharmaceuticals, Inc. based upon or rising out of Agency’s negligence, willful misconduct, or any breach of its obligations or warranties contained in this Agreement.

 

China Qinba Pharmaceuticals Inc. agrees to indemnify and hold harmless Agency from and against all losses, claims, damages, expenses or liabilities which it may incur based on information, representation, reports or data furnished to the Agency by the Company, to the extent that such material is relied upon by the Agency and directly
incorporated by Agency to provide services to the Company under this Agreement.

 

NOTICES.  All notices, approvals and other communications hereunder shall be effective only if in writing and either personally delivered or sent by registered or certified mail, return receipt requested, or by express mail or air express,
or via electronic mail.

 

TERMINATION.  Notwithstanding anything to the contrary contained elsewhere herein, China Qinba Pharmaceuticals, Inc. shall have the right to terminate this Agreement for any reason whatsoever by sixty (60) day written notice to Agency.  In
the event of such termination, China Qinba Pharmaceuticals Inc. shall be released from all obligations under this Agreement, provided that China Qinba Pharmaceuticals Inc. agrees to pay Agency for services performed hereunder prior to the date of termination on a pro-rata basis. Furthermore, upon termination, Agency shall immediately deliver to China Qinba Pharmaceuticals Inc. all elements and related materials then in Agency’s possession relating to China Qinba Pharmaceuticals Inc. and China Qinba Pharmaceuticals
Inc. shall have the right to use all materials and information created by Agency under this Agreement.  No termination of Agency’s services hereunder shall affect China Qinba Pharmaceuticals Inc.’s rights in or to the results and proceeds of Agency’s services theretofore rendered hereunder, or China Qinba Pharmaceuticals Inc.’s rights at law and in equity, nor shall any termination affect any other rights granted to China Qinba Pharmaceuticals Inc. by Agency hereunder.

 

GOVERNING LAW.   This agreement shall be deemed made in the State of New York and shall be construed in accordance with the laws of New York applicable to contracts entirely made and performed therein.

  

2

  

 

ENTIRE AGREEMENT.   The Agreement constitutes the entire understanding between the parties with respect to Agency’s services hereunder and supersedes all prior negotiations and understandings relating
thereto.

 

REGISTRATION RIGHTS.  The Company will cause a registration statement to be filed with the U.S. Securities and Exchange Commission, covering 100% of the common stock underlying the Warrants, on or before May 31, 2010 and use its commercially reasonable efforts
to cause the registration statement to become effective within one hundred eighty (180) days following the date of this Agreement.  The Company will also use commercially reasonable efforts to maintain the effectiveness of the registration statement for a period of 3 years from the date of this Agreement.

 

The Company will be deemed not to have used commercially reasonable efforts to cause the registration statement to become, or to remain effective during the requisite period if the Company voluntarily takes any action that would, or omits any action the omission of which would result in either: (i) such registration statement not being declared effective; or (ii) the
holders of securities covered by a previously effective registration statement being prohibited by applicable law from trading the securities covered thereby.

 

The aggregate amount of liquidated damages payable by the Company to the Agency as a result of a failure to timely file, or cause the registration statement to become or maintain its effective status, shall be capped at ten percent (10%) of the market value of the common stock underlying the Warrants at the time of breach.  Moreover, the Company shall not accrue
liquidated damages with respect to more than one of any failure under this section at a time.

 

The Agreement may not be modified or amended except by written instrument signed by the parties hereto.  The invalidity or illegality of any party of this Agreement shall not affect the validity or enforceability of any other part hereof.

  

3

  

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

 

China Qinba Pharmaceuticals Inc.

 

By: ______________________________

Wang Guozhu, Chairman and Chief Executive Officer

Date: January 27, 2010

 

 

HACG Investor Relations Services Inc

 

By: _______________________________

Min Zhou, Principal

Date: January 27, 2010

 

 

 

 

 

 

 

 

 

 

 

  

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00168-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00168-of-00352.parquet"}]]